Insider Buying: Neonc Technologies (NASDAQ:NTHI) CMO Buys $10,003.92 in Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CMO Thomas Chen acquired 2,284 shares of the firm’s stock in a transaction on Tuesday, November 10th. The stock was acquired at an average cost of $4.38 per share, with a total value of $10,003.92. Following the acquisition, the chief marketing officer owned 29,519 shares of the company’s stock, valued at $129,293.22. This trade represents a 8.39% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Neonc Technologies Price Performance

Shares of NASDAQ:NTHI opened at $4.52 on Thursday. Neonc Technologies Holdings, Inc. has a 1-year low of $2.50 and a 1-year high of $12.00. The company’s fifty day moving average is $3.30 and its two-hundred day moving average is $5.31.

Neonc Technologies (NASDAQ:NTHI) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.03).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Global Retirement Partners LLC acquired a new stake in shares of Neonc Technologies in the second quarter valued at approximately $126,000. BlackRock Inc. acquired a new position in shares of Neonc Technologies during the second quarter worth approximately $815,000. Westmount Partners LLC grew its holdings in Neonc Technologies by 355.2% in the 2nd quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock worth $893,000 after buying an additional 153,858 shares in the last quarter. Finally, Bank of America Corp DE bought a new position in Neonc Technologies in the 2nd quarter worth approximately $1,017,000.

Analysts Set New Price Targets

NTHI has been the topic of a number of research reports. BTIG Research reiterated a “buy” rating and set a $15.00 price target on shares of Neonc Technologies in a research report on Tuesday, September 8th. Zacks Research upgraded Neonc Technologies from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 5th. Wall Street Zen raised Neonc Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, November 7th. Weiss Ratings lowered Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, October 21st. Finally, Roth Capital began coverage on Neonc Technologies in a research note on Thursday, September 24th. They issued a “buy” rating on the stock. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Neonc Technologies currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Neonc Technologies Company Profile

NeOnc Technologies Holdings, Inc. is a biotechnology company developing treatments for brain tumors and other central nervous system cancers. Its research focuses on approaches intended to deliver therapies to the brain, where the blood-brain barrier can limit the effectiveness of conventional treatments. The company’s pipeline includes NEO100, a formulation of perillyl alcohol designed for intranasal delivery, and NEO212, a compound combining perillyl alcohol with temozolomide. These candidates are being developed for potential use in brain cancer treatment.